Products

We have focused our pipeline of product candidates on biologics that we believe can be enhanced by the LEX System. The LEX System facilitates the development of proteins whose complexity and other properties limit their commercial viability in traditional production systems. It also enables us to produce monoclonal antibodies that can be optimized with the objective of improving their potency and efficacy.

By capitalizing on the significant benefits of the LEX System over traditional production systems, we are developing the following pipeline of product candidates that includes Locteron®, BLX-155 and BLX-301.

	Only controlled-release interferon alpha Two Phase 2b trials to be presented at EASL 2010 Phase 3 ready in 2011 Patent protection through 2028	Interferon is $2.5 billion market expected to grow $6 billion Current interferons have severe side effects Locteron market research projects $2.7 billion in peak sales and $2.1 billion NPV	More tolerable and milder side effects More convenient dosing Strong anti-viral response Next major HCV drug to be launched after Telaprevir and Boceprevir
	Recombinant Plasmin More effective and safer clot buster Can only be made in LEX System		Anti-CD20 antibody with optimized glycosylation structure Greater efficacy and potency with fewer side effects

Return to top